Contrasting Merus (MRUS) and Its Rivals
Merus (NASDAQ: MRUS) is one of 285 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its peers? We will compare Merus to related businesses based on the strength of its analyst recommendations, valuation, risk, earnings, dividends, profitability and institutional ownership.
This is a breakdown of current ratings and recommmendations for Merus and its peers, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Insider and Institutional Ownership
30.1% of Merus shares are owned by institutional investors. Comparatively, 50.2% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 17.1% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Risk and Volatility
Merus has a beta of -0.2, suggesting that its share price is 120% less volatile than the S&P 500. Comparatively, Merus’ peers have a beta of 0.56, suggesting that their average share price is 44% less volatile than the S&P 500.
Valuation and Earnings
This table compares Merus and its peers revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Merus||$3.01 million||-$52.26 million||-2.62|
|Merus Competitors||$284.28 million||$34.29 million||133.20|
Merus’ peers have higher revenue and earnings than Merus. Merus is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
This table compares Merus and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Merus peers beat Merus on 7 of the 12 factors compared.
Merus Company Profile
Merus NV is a biotechnology company based in the Netherlands. The Company develops differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Biclonics format. Its products inlcude, among others, MCLA-134 that is designed to bind to a combination of two immunomodulatory targets expressed by T cells, as wellas MCLA-145 that is designed to bind to a tumor-associated target with an immunomodulatory target involved in checkpoint inhibition.
Receive News & Ratings for Merus NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus NV and related companies with MarketBeat.com's FREE daily email newsletter.